CARB-X funds Eligo Bioscience to develop CRISPR-based therapeutics

CARB-X funds Eligo Bioscience to develop CRISPR-based therapeutics

  • 30/06/2020

With a unique approach, Eligo engineers natural predators of bacteria to deliver CRISPR systems that kill antibiotic-resistant superbugs in the gut microbiome.

CARB-X announced that it is awarding up to US$1.82 million to Eligo Bioscience in Paris, France, with additional funding for a total award of up to US$7.05 million if project milestones are met, for the development of a new generation of highly-specific antimicrobials to prevent multi-drug-resistant bacterial infections in organ transplant patients. Eligo’s bacteriophage- and CRISPR-based therapeutics are designed to selectively eliminate extended-spectrum beta-lactamase-producing (ESBL) and Carbapenem-resistant E. coli and K. Pneumoniae (CRE) from the microbiome of transplant patients before their procedure, thereby preventing the onset of these often-fatal infections.

Read more: https://carb-x.org/carb-x-news/carb-x-funds-eligo-bioscience-to-develop-crispr-based-therapeutics-derived-from-bacteriophages-to-kill-superbugs-and-prevent-deadly-infections-in-transplant-patients/